P3.17-22 Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable NSCLC

Authors :: Bo Lu
Grace L. Lu-Yao
R. Axelrod
Dawn Poller
Maria Werner-Wasik
Ralph Zinner
D.C. Hooper
Scott W. Cowan
B. Leiby
C. Solomides
Hushan Yang
Jennifer Johnson
L. Harshyne
Athanassios Argiris
Nathaniel R. Evans
L. Phan
Source :: Journal of Thoracic Oncology. 13:S1028-S1029
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: Pulmonary and Respiratory Medicine
Cisplatin
Pemetrexed
Oncology
business.industry
medicine
Cancer research
Cisplatin/gemcitabine
Nivolumab
business
medicine.drug

Full Text Access

Tools